Hideya Seo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hideya Seo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Anabel Flores
Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, UCSD, La Jolla, California, USA
1 shared publication Angelica Montenegro Riestra
Department of Biology, San Diego State University, San Diego, California, USA
1 shared publication- Armin Kousha
Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, UCSD, La Jolla, California, USA
1 shared publication - Elisabet Bjånes
Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California San Diego
1 shared publication - Fatemeh Askarian
Department of Pediatrics, University of California San Diego
1 shared publication - George Sakoulas
University of California San Diego School of Medicine, La Jolla, California, USA
1 shared publication
Latest Publications
- 20 August 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Effects of Electrical Muscle Stimulation on Skeletal Muscle During Lipopolysaccharide-Induced Inflammation: A Controlled Murine Study
BACKGROUND: Electrical muscle stimulation (EMS) is used in critically ill patients to prevent intensive care unit-acquired weakness. It promotes anabolic responses partly through interleukin-6 (IL-6) signaling under non-inflammatory conditions; however, its effects during systemic inflammation remain unclear. We hypothesized that EMS applied during lipopolysaccharide (LPS)-induced systemic inflammation exacerbates skeletal muscle atrophy through activation of IL-6-mediated catabolic signaling. METHODS: Male C57BL/6J mice were randomly assigned to control, EMS, LPS, or EMS/LPS groups. Intraperitoneal LPS (2 mg/kg) or phosphate-buffered saline was administered, followed by EMS applied to the left hindlimb 8 h later (80 Hz, 5 mA, 30 min). Gastrocnemius muscle fiber cross-sectional area (CSA) was measured as an index of muscle atrophy, with three mice analyzed per group. Gastrocnemius muscles and blood samples were collected after treatment, and muscle morphology and CSA were analyzed histologically. Protein expression of Atrogin-1, MuRF1, C/EBPδ, phosphorylated mTOR, p70S6K, and STAT3 was assessed by Western blot, and IL-6 expression by qRT-PCR and ELISA. Data are presented as mean ± standard deviation (SD). RESULTS: Compared with control, EMS alone increased CSA (mean ± SD,1610 ± 468 vs 1350 ± 437 μm 2 ; P < .0001), and the phosphorylation of mTOR (1.72 ± 0.234-fold; P < .0001) and p70S6K (2.34 ± 0.559-fold; P < .0001). In contrast, compared with LPS alone, EMS applied under LPS did not enhance the phosphorylation of mTOR or p70S6K, but reduced muscle fiber CSA (680 ± 327 vs 991 ± 453 μm 2 ; P < .0001), and upregulated Atrogin-1 (13.1 ± 3.72 vs 7.85 ± 2.26-fold; p = 0.0014) and MuRF1 (3.77 ± 1.45 vs 2.50 ± 0.998 -fold; p = 0.0094) expression. These catabolic changes were accompanied by increased STAT3 phosphorylation and C/EBPδ expression (8.28 ± 4.16 vs 4.56 ± 1.88 -fold; p = 0.0098, 39.2 ± 16.4 vs 22.8 ± 12.3-fold; p = 0.0107). Additionally, IL-6 expression was elevated in both stimulated muscle (335 ± 242 vs 140 ± 23.1-fold; p = 0.0095) and serum (28.5 ± 4.60 vs 9.35 ± 3.19 ng/mL; P < .0001) in the EMS/LPS group. Similar atrophic changes were observed in the contralateral, non-stimulated limb. CONCLUSIONS: EMS applied during LPS-induced systemic inflammation exacerbated skeletal muscle atrophy and was associated with activation of IL-6/STAT3–C/EBPδ signaling and proteolytic pathways. These findings provide mechanistic insight into the effects of EMS under inflammatory conditions and warrant further investigation.
- 20 August 2026
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
Effects of Electrical Muscle Stimulation on Skeletal Muscle During Lipopolysaccharide-Induced Inflammation: A Controlled Murine Study
BACKGROUND: Electrical muscle stimulation (EMS) is used in critically ill patients to prevent intensive care unit-acquired weakness. It promotes anabolic responses partly through interleukin-6 (IL-6) signaling under non-inflammatory conditions; however, its effects during systemic inflammation remain unclear. We hypothesized that EMS applied during lipopolysaccharide (LPS)-induced systemic inflammation exacerbates skeletal muscle atrophy through activation of IL-6-mediated catabolic signaling. METHODS: Male C57BL/6J mice were randomly assigned to control, EMS, LPS, or EMS/LPS groups. Intraperitoneal LPS (2 mg/kg) or phosphate-buffered saline was administered, followed by EMS applied to the left hindlimb 8 h later (80 Hz, 5 mA, 30 min). Gastrocnemius muscle fiber cross-sectional area (CSA) was measured as an index of muscle atrophy, with three mice analyzed per group. Gastrocnemius muscles and blood samples were collected after treatment, and muscle morphology and CSA were analyzed histologically. Protein expression of Atrogin-1, MuRF1, C/EBPδ, phosphorylated mTOR, p70S6K, and STAT3 was assessed by Western blot, and IL-6 expression by qRT-PCR and ELISA. Data are presented as mean ± standard deviation (SD). RESULTS: Compared with control, EMS alone increased CSA (mean ± SD,1610 ± 468 vs 1350 ± 437 μm 2 ; P < .0001), and the phosphorylation of mTOR (1.72 ± 0.234-fold; P < .0001) and p70S6K (2.34 ± 0.559-fold; P < .0001). In contrast, compared with LPS alone, EMS applied under LPS did not enhance the phosphorylation of mTOR or p70S6K, but reduced muscle fiber CSA (680 ± 327 vs 991 ± 453 μm 2 ; P < .0001), and upregulated Atrogin-1 (13.1 ± 3.72 vs 7.85 ± 2.26-fold; p = 0.0014) and MuRF1 (3.77 ± 1.45 vs 2.50 ± 0.998 -fold; p = 0.0094) expression. These catabolic changes were accompanied by increased STAT3 phosphorylation and C/EBPδ expression (8.28 ± 4.16 vs 4.56 ± 1.88 -fold; p = 0.0098, 39.2 ± 16.4 vs 22.8 ± 12.3-fold; p = 0.0107). Additionally, IL-6 expression was elevated in both stimulated muscle (335 ± 242 vs 140 ± 23.1-fold; p = 0.0095) and serum (28.5 ± 4.60 vs 9.35 ± 3.19 ng/mL; P < .0001) in the EMS/LPS group. Similar atrophic changes were observed in the contralateral, non-stimulated limb. CONCLUSIONS: EMS applied during LPS-induced systemic inflammation exacerbated skeletal muscle atrophy and was associated with activation of IL-6/STAT3–C/EBPδ signaling and proteolytic pathways. These findings provide mechanistic insight into the effects of EMS under inflammatory conditions and warrant further investigation.
- Open Access
- 15 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (12)
Colistin exerts potent activity against mcr+ Enterobacteriaceae via synergistic interactions with the host defense
Colistin (COL) is a cationic cyclic peptide that disrupts the membranes of Gram-negative bacteria and is often used as a last resort antibiotic against multidrug-resistant strains. The emergence of plasmid-borne mcr genes, which confer transferable COL resistance, has raised serious concerns, particularly in strains also carrying extended-spectrum β-lactamase and carbapenemase genes. Standard antimicrobial susceptibility testing (AST), performed in enriched bacteriological media, indicates no activity of COL against mcr + strains, leading to its exclusion from treatment regimens. However, these media poorly reflect in vivo physiology and lack host immune components. Here we show that COL retained bactericidal activity against mcr-1 + Escherichia coli , Klebsiella pneumoniae , and Salmonella enterica when tested in tissue culture medium containing physiological bicarbonate. COL enhanced serum complement deposition on bacterial surfaces and synergized with human serum to kill pathogens. At clinically achievable concentrations, COL killed mcr-1 + strains in freshly isolated human blood and was effective as monotherapy in a murine E . coli bacteremia model. These findings suggest that COL, currently dismissed based on conventional AST, may offer clinical benefit against mcr-1 + infections when evaluated under more physiological conditions — warranting reconsideration in clinical microbiology practices and future trials for high-risk patients.
- 15 April 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (12)
Open AccessColistin exerts potent activity against mcr+ Enterobacteriaceae via synergistic interactions with the host defense
Colistin (COL) is a cationic cyclic peptide that disrupts the membranes of Gram-negative bacteria and is often used as a last resort antibiotic against multidrug-resistant strains. The emergence of plasmid-borne mcr genes, which confer transferable COL resistance, has raised serious concerns, particularly in strains also carrying extended-spectrum β-lactamase and carbapenemase genes. Standard antimicrobial susceptibility testing (AST), performed in enriched bacteriological media, indicates no activity of COL against mcr + strains, leading to its exclusion from treatment regimens. However, these media poorly reflect in vivo physiology and lack host immune components. Here we show that COL retained bactericidal activity against mcr-1 + Escherichia coli , Klebsiella pneumoniae , and Salmonella enterica when tested in tissue culture medium containing physiological bicarbonate. COL enhanced serum complement deposition on bacterial surfaces and synergized with human serum to kill pathogens. At clinically achievable concentrations, COL killed mcr-1 + strains in freshly isolated human blood and was effective as monotherapy in a murine E . coli bacteremia model. These findings suggest that COL, currently dismissed based on conventional AST, may offer clinical benefit against mcr-1 + infections when evaluated under more physiological conditions — warranting reconsideration in clinical microbiology practices and future trials for high-risk patients.